Annexon, Inc. (NASDAQ:ANNX) Shares Sold by Virtu Financial LLC

Virtu Financial LLC cut its position in shares of Annexon, Inc. (NASDAQ:ANNX) by 35.4% in the 3rd quarter, according to the company in its most recent disclosure with the SEC. The fund owned 19,165 shares of the company’s stock after selling 10,499 shares during the quarter. Virtu Financial LLC’s holdings in Annexon were worth $113,000 as of its most recent filing with the SEC.

A number of other institutional investors also recently bought and sold shares of the company. Point72 Asset Management L.P. raised its stake in shares of Annexon by 16.1% during the 2nd quarter. Point72 Asset Management L.P. now owns 5,989,017 shares of the company’s stock worth $29,346,000 after buying an additional 832,617 shares during the last quarter. Point72 Europe London LLP acquired a new position in Annexon during the second quarter worth about $1,150,000. Charles Schwab Investment Management Inc. lifted its holdings in shares of Annexon by 221.8% in the third quarter. Charles Schwab Investment Management Inc. now owns 732,216 shares of the company’s stock valued at $4,335,000 after purchasing an additional 504,656 shares in the last quarter. FMR LLC grew its position in shares of Annexon by 3.2% in the third quarter. FMR LLC now owns 8,561,949 shares of the company’s stock valued at $50,687,000 after purchasing an additional 262,229 shares during the last quarter. Finally, Mutual of America Capital Management LLC acquired a new stake in shares of Annexon in the second quarter valued at approximately $3,134,000.

Insider Buying and Selling

In related news, EVP Ted Yednock sold 5,408 shares of the company’s stock in a transaction that occurred on Tuesday, October 15th. The shares were sold at an average price of $7.41, for a total transaction of $40,073.28. Following the completion of the transaction, the executive vice president now owns 71,365 shares of the company’s stock, valued at approximately $528,814.65. This represents a 7.04 % decrease in their ownership of the stock. The sale was disclosed in a document filed with the SEC, which is accessible through this hyperlink. 12.67% of the stock is currently owned by company insiders.

Analyst Upgrades and Downgrades

A number of research firms recently issued reports on ANNX. Needham & Company LLC reaffirmed a “buy” rating and issued a $16.00 target price on shares of Annexon in a research note on Friday, November 15th. HC Wainwright restated a “buy” rating and issued a $30.00 price objective on shares of Annexon in a research report on Tuesday. Finally, Cantor Fitzgerald reiterated an “overweight” rating on shares of Annexon in a research report on Friday, November 15th. Six research analysts have rated the stock with a buy rating, According to data from MarketBeat, Annexon presently has a consensus rating of “Buy” and an average target price of $15.80.

Annexon Stock Up 5.5 %

ANNX stock opened at $5.22 on Friday. The stock has a market capitalization of $556.42 million, a price-to-earnings ratio of -4.97 and a beta of 1.10. Annexon, Inc. has a 52-week low of $2.77 and a 52-week high of $8.40. The stock’s fifty day simple moving average is $6.21 and its 200-day simple moving average is $5.97.

About Annexon

Annexon, Inc, a clinical-stage biopharmaceutical company, discovers and develops medicines for treating inflammatory-related diseases. Its lead candidate is ANX005, an investigational full-length monoclonal antibody, which is in Phase 3 clinical trial for the treatment of patients with guillain-barré syndrome; completed Phase II clinical trial for treating Huntington's disease; and in Phase II clinical trial for the treatment of amyotrophic lateral sclerosis.